MX2009002960A - Inhibidores de serina hidrolasa. - Google Patents

Inhibidores de serina hidrolasa.

Info

Publication number
MX2009002960A
MX2009002960A MX2009002960A MX2009002960A MX2009002960A MX 2009002960 A MX2009002960 A MX 2009002960A MX 2009002960 A MX2009002960 A MX 2009002960A MX 2009002960 A MX2009002960 A MX 2009002960A MX 2009002960 A MX2009002960 A MX 2009002960A
Authority
MX
Mexico
Prior art keywords
serine hydrolase
compounds
hydrolase inhibitors
compositions
useful
Prior art date
Application number
MX2009002960A
Other languages
English (en)
Inventor
Yasushi Kohno
Kevin Shreder
Yi Hu
Allister Fraser
Yunichi Ishiyama
Akihiko Kojima
Original Assignee
Activx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activx Biosciences Inc filed Critical Activx Biosciences Inc
Publication of MX2009002960A publication Critical patent/MX2009002960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

En la presente se proporcionan compuestos benzoxazinona de la fórmula (I): (ver fórmula (I)) y las composiciones de contienen los compuestos. Los compuestos y composiciones son útiles en los métodos para inhibir la acción de la serina hidrolasa, incluida la neutrófilo elastasa. En ciertas modalidades, los compuestos y composiciones son útiles para la prevención, mejoramiento o tratamiento de enfermedades mediadas por la serina hidrolasa.
MX2009002960A 2006-09-21 2007-09-20 Inhibidores de serina hidrolasa. MX2009002960A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84654506P 2006-09-21 2006-09-21
PCT/US2007/020427 WO2008036379A2 (en) 2006-09-21 2007-09-20 Serine hydrolase inhibitors

Publications (1)

Publication Number Publication Date
MX2009002960A true MX2009002960A (es) 2009-06-26

Family

ID=39126272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002960A MX2009002960A (es) 2006-09-21 2007-09-20 Inhibidores de serina hidrolasa.

Country Status (17)

Country Link
US (1) US7879846B2 (es)
EP (1) EP2066662B1 (es)
JP (1) JP5377313B2 (es)
KR (1) KR20090068263A (es)
CN (1) CN101535304A (es)
AU (1) AU2007297597B2 (es)
BR (1) BRPI0716897A2 (es)
CA (1) CA2664152C (es)
DK (1) DK2066662T3 (es)
ES (1) ES2396256T3 (es)
MX (1) MX2009002960A (es)
NO (1) NO20091353L (es)
NZ (1) NZ575907A (es)
PL (1) PL2066662T3 (es)
PT (1) PT2066662E (es)
WO (1) WO2008036379A2 (es)
ZA (1) ZA200902091B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704958B1 (en) * 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
KR20140015134A (ko) * 2009-09-25 2014-02-06 교린 세이야꾸 가부시키 가이샤 말레산염 및 그의 결정
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US20130317215A1 (en) 2010-11-30 2013-11-28 Kyorin Pharmaceutical Co., Ltd. Stable synthetic intermediate and method for manufacturing same
EP2647636A4 (en) * 2010-11-30 2014-11-12 Kyorin Seiyaku Kk PROCESS FOR PRODUCTION OF MALATEATE USING WET CRYSTALS
CN103145666B (zh) * 2013-03-27 2015-04-22 山东省科学院生物研究所 4-取代α-吡喃酮衍生物及其制备方法与应用
EA037555B1 (ru) 2015-04-02 2021-04-13 Проксимэйджен, Элэлси Применение 6-{4-[1-(пропан-2-ил)пиперидин-4-ил]-1,4-диазепан-1-ил}-n-(пиридин-4-ил)пиридин-2-карбоксамида для лечения раковых заболеваний цнс
CN107033135B (zh) 2017-05-26 2020-09-11 浙江省诸暨合力化学对外贸易有限公司 一种制备异噁嗪酮化合物的方法及其应用
JP2023500182A (ja) 2019-09-17 2023-01-05 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
EP4252850A3 (en) 2020-04-16 2023-11-15 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2914915A1 (de) 1979-04-12 1980-10-30 Basf Ag 4h-3,1-benzoxazinderivate
DE3000309A1 (de) 1980-01-05 1981-07-09 Basf Ag, 6700 Ludwigshafen 4h-3,1-benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4430669A (en) * 1981-05-29 1984-02-07 Payview Limited Transmitting and receiving apparatus for permitting the transmission and reception of multi-tier subscription programs
JPS57209979A (en) 1981-06-19 1982-12-23 Teijin Ltd Ultraviolet light absorber and method for using same
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS60169469A (ja) * 1983-12-27 1985-09-02 シンテツクス（ユ−・エス・エイ）インコ−ポレイテツド ４ｈ−１，３−ベンズオキサジン−４−オン化合物
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH07316056A (ja) * 1990-02-15 1995-12-05 Teijin Ltd エラスターゼ阻害用医薬組成物
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5274560A (en) * 1990-12-03 1993-12-28 Audio Navigation Systems, Inc. Sensor free vehicle navigation system utilizing a voice input/output interface for routing a driver from his source point to his destination point
US5332734A (en) * 1991-04-10 1994-07-26 Japan Tobacco, Incorporated Oxazinone derivative
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5377350A (en) * 1993-04-30 1994-12-27 International Business Machines Corporation System for cooperative communication between local object managers to provide verification for the performance of remote calls by object messages
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
DE69423838T2 (de) * 1993-09-23 2000-08-03 Xerox Corp Semantische Gleichereignisfilterung für Spracherkennung und Signalübersetzungsanwendungen
JPH07309851A (ja) 1994-05-16 1995-11-28 Fuji Chem Ind Co Ltd ベンゾオキサジノン誘導体の製造方法
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5696965A (en) * 1994-11-03 1997-12-09 Intel Corporation Electronic information appraisal agent
DE69514624T2 (de) 1994-11-08 2000-08-31 Teijin Ltd Methode zur Verhinderung der Fluoreszenzemission aus Polyalkylennaphthalin-2,6-dicarboxylat
US6001814A (en) 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors
US20020119985A1 (en) 1994-11-21 2002-08-29 Albert Gyorkos Serine protease inhibitors
US6001811A (en) 1994-11-21 1999-12-14 Cortech Inc. Serine protease inhibitors--N-substituted derivatives
US6001813A (en) 1994-11-21 1999-12-14 Cortech Inc. Val-pro containing α-keto oxadiazoles as serine protease inhibitors
US6150334A (en) 1994-11-21 2000-11-21 Cortech, Inc. Serine protease inhibitors-tripeptoid analogs
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5774859A (en) * 1995-01-03 1998-06-30 Scientific-Atlanta, Inc. Information system having a speech interface
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5795890A (en) 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6314420B1 (en) * 1996-04-04 2001-11-06 Lycos, Inc. Collaborative/adaptive search engine
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US5878385A (en) * 1996-09-16 1999-03-02 Ergo Linguistic Technologies Method and apparatus for universal parsing of language
EP1007012A4 (en) 1996-10-01 2006-01-18 Cima Labs Inc TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5902347A (en) * 1996-11-19 1999-05-11 American Navigation Systems, Inc. Hand-held GPS-mapping device
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
JPH10251239A (ja) * 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6195634B1 (en) * 1997-12-24 2001-02-27 Nortel Networks Corporation Selection of decoys for non-vocabulary utterances rejection
HUP0100221A3 (en) 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6574597B1 (en) * 1998-05-08 2003-06-03 At&T Corp. Fully expanded context-dependent networks for speech recognition
JPH11322611A (ja) 1998-05-14 1999-11-24 Sankyo Co Ltd 抗ウイルス剤
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6570555B1 (en) * 1998-12-30 2003-05-27 Fuji Xerox Co., Ltd. Method and apparatus for embodied conversational characters with multimodal input/output in an interface device
US6757718B1 (en) * 1999-01-05 2004-06-29 Sri International Mobile navigation of network-based electronic information using spoken input
US6567797B1 (en) * 1999-01-26 2003-05-20 Xerox Corporation System and method for providing recommendations based on multi-modal user clusters
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6643620B1 (en) * 1999-03-15 2003-11-04 Matsushita Electric Industrial Co., Ltd. Voice activated controller for recording and retrieving audio/video programs
US6631346B1 (en) * 1999-04-07 2003-10-07 Matsushita Electric Industrial Co., Ltd. Method and apparatus for natural language parsing using multiple passes and tags
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6804638B2 (en) * 1999-04-30 2004-10-12 Recent Memory Incorporated Device and method for selective recall and preservation of events prior to decision to record the events
US20020032564A1 (en) * 2000-04-19 2002-03-14 Farzad Ehsani Phrase-based dialogue modeling with particular application to creating a recognition grammar for a voice-controlled user interface
CN1481245A (zh) * 1999-07-12 2004-03-10 G.D.瑟尔及两合公司 用于治疗单纯疱疹病毒的2－氨基苯并噁嗪酮
US6513006B2 (en) * 1999-08-26 2003-01-28 Matsushita Electronic Industrial Co., Ltd. Automatic control of household activity using speech recognition and natural language
US6415257B1 (en) * 1999-08-26 2002-07-02 Matsushita Electric Industrial Co., Ltd. System for identifying and adapting a TV-user profile by means of speech technology
US6901366B1 (en) * 1999-08-26 2005-05-31 Matsushita Electric Industrial Co., Ltd. System and method for assessing TV-related information over the internet
US6598018B1 (en) * 1999-12-15 2003-07-22 Matsushita Electric Industrial Co., Ltd. Method for natural dialog interface to car devices
US6466654B1 (en) * 2000-03-06 2002-10-15 Avaya Technology Corp. Personal virtual assistant with semantic tagging
JP2001250689A (ja) 2000-03-07 2001-09-14 Toray Ind Inc 発光素子
EP1174430A1 (en) 2000-07-20 2002-01-23 Universität Konstanz Process for the preparation of heterocycles by using C1-building blocks
US6922670B2 (en) * 2000-10-24 2005-07-26 Sanyo Electric Co., Ltd. User support apparatus and system using agents
US6795808B1 (en) * 2000-10-30 2004-09-21 Koninklijke Philips Electronics N.V. User interface/entertainment device that simulates personal interaction and charges external database with relevant data
US6721706B1 (en) * 2000-10-30 2004-04-13 Koninklijke Philips Electronics N.V. Environment-responsive user interface/entertainment device that simulates personal interaction
US6735592B1 (en) * 2000-11-16 2004-05-11 Discern Communications System, method, and computer program product for a network-based content exchange system
US20020065568A1 (en) * 2000-11-30 2002-05-30 Silfvast Robert Denton Plug-in modules for digital signal processor functionalities
US20020082911A1 (en) * 2000-12-22 2002-06-27 Dunn Charles L. Online revenue sharing
EP1231788A1 (en) * 2001-02-12 2002-08-14 Koninklijke Philips Electronics N.V. Arrangement for distributing content, profiling center, receiving device and method
US6804684B2 (en) * 2001-05-07 2004-10-12 Eastman Kodak Company Method for associating semantic information with multiple images in an image database environment
US6944594B2 (en) * 2001-05-30 2005-09-13 Bellsouth Intellectual Property Corporation Multi-context conversational environment system and method
JP2003005897A (ja) * 2001-06-20 2003-01-08 Alpine Electronics Inc 情報入力方法および装置
US20020198714A1 (en) * 2001-06-26 2002-12-26 Guojun Zhou Statistical spoken dialog system
MY142967A (en) * 2001-08-13 2011-01-31 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
AR036872A1 (es) * 2001-08-13 2004-10-13 Du Pont Compuesto de antranilamida, composicion que lo comprende y metodo para controlar una plaga de invertebrados
US7289606B2 (en) * 2001-10-01 2007-10-30 Sandeep Sibal Mode-swapping in multi-modal telephonic applications
US7640006B2 (en) * 2001-10-03 2009-12-29 Accenture Global Services Gmbh Directory assistance with multi-modal messaging
US6774232B2 (en) 2001-10-22 2004-08-10 Cytec Technology Corp. Low color, low sodium benzoxazinone UV absorbers and process for making same
GB2383247A (en) * 2001-12-13 2003-06-18 Hewlett Packard Co Multi-modal picture allowing verbal interaction between a user and the picture
US7127400B2 (en) * 2002-05-22 2006-10-24 Bellsouth Intellectual Property Corporation Methods and systems for personal interactive voice response
US7398209B2 (en) * 2002-06-03 2008-07-08 Voicebox Technologies, Inc. Systems and methods for responding to natural language speech utterance
TWI326283B (en) 2002-07-31 2010-06-21 Du Pont Method for preparing fused oxazinones
EP1394692A1 (en) * 2002-08-05 2004-03-03 Alcatel Method, terminal, browser application, and mark-up language for multimodal interaction between a user and a terminal
US7146319B2 (en) * 2003-03-31 2006-12-05 Novauris Technologies Ltd. Phonetically based speech recognition system and method
PT1631295E (pt) 2003-06-06 2010-05-24 Arexis Ab Uso de compostos heterocíclicos condensados como inibidores de scce para o tratamento de doenças da pele
JP2005003926A (ja) * 2003-06-11 2005-01-06 Sony Corp 情報処理装置および方法、並びにプログラム
JP4543043B2 (ja) 2003-06-12 2010-09-15 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 縮合オキサジノンの製造方法
WO2005018532A2 (en) 2003-08-25 2005-03-03 Actar Ab Purine receptor binding compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
BRPI0512075A (pt) 2004-06-15 2008-02-06 Astrazeneca Ab composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
GB0422556D0 (en) 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
US7376645B2 (en) * 2004-11-29 2008-05-20 The Intellection Group, Inc. Multimodal natural language query system and architecture for processing voice and proximity-based queries
US7424431B2 (en) * 2005-07-11 2008-09-09 Stragent, Llc System, method and computer program product for adding voice activation and voice control to a media player
US7640160B2 (en) * 2005-08-05 2009-12-29 Voicebox Technologies, Inc. Systems and methods for responding to natural language speech utterance
US7620549B2 (en) * 2005-08-10 2009-11-17 Voicebox Technologies, Inc. System and method of supporting adaptive misrecognition in conversational speech
US7949529B2 (en) * 2005-08-29 2011-05-24 Voicebox Technologies, Inc. Mobile systems and methods of supporting natural language human-machine interactions
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US8073681B2 (en) * 2006-10-16 2011-12-06 Voicebox Technologies, Inc. System and method for a cooperative conversational voice user interface

Also Published As

Publication number Publication date
CN101535304A (zh) 2009-09-16
EP2066662A2 (en) 2009-06-10
US7879846B2 (en) 2011-02-01
CA2664152C (en) 2014-09-30
ZA200902091B (en) 2010-07-28
WO2008036379A2 (en) 2008-03-27
AU2007297597B2 (en) 2013-02-21
AU2007297597A1 (en) 2008-03-27
PT2066662E (pt) 2013-02-13
NO20091353L (no) 2009-05-19
NZ575907A (en) 2011-03-31
US20080161290A1 (en) 2008-07-03
KR20090068263A (ko) 2009-06-25
ES2396256T3 (es) 2013-02-20
CA2664152A1 (en) 2008-03-27
BRPI0716897A2 (pt) 2013-10-22
PL2066662T3 (pl) 2013-05-31
EP2066662B1 (en) 2012-12-05
WO2008036379A3 (en) 2008-05-08
JP5377313B2 (ja) 2013-12-25
DK2066662T3 (da) 2013-01-07
JP2010504334A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
MX2009002960A (es) Inhibidores de serina hidrolasa.
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX342128B (es) Compuestos farmaceuticos.
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
SG164368A1 (en) Treatment of cancer
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
PH12014500053A1 (en) Proteasome inhibitors
MX2009004707A (es) Piridina carboxamides como inhibidores 11-beta-hsd1.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
UA85559C2 (en) Aminobenzophenone compounds
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
TN2010000074A1 (en) Cyclic depsipeptides
MX2010002296A (es) Inhibidores iv de polimerasa de fosfadiazina hcv.
WO2007097981A3 (en) Alpha carbolines and uses thereof

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights
FG Grant or registration